| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ali Talaei, Farhad Farid Hosseini, Zahra Aghili, Shahin Akhondzadeh, Elham Asadpour, Neema John Mehramiz, Fatemeh Forouzanfa. Correction: A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Canadian journal of physiology and pharmacology. vol 98. issue 6. 2020-07-10. PMID:32383985. |
correction: a comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder. |
2020-07-10 |
2023-08-13 |
Not clear |
| Dong-Dong Zhou, Xiao-Xin Zhou, Zhen Lv, Xiao-Rong Chen, Wo Wang, Gao-Mao Wang, Chuan Liu, Da-Qi Li, Li Kuan. Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: A network meta-analysis. Journal of psychiatric research. vol 111. 2020-06-17. PMID:30677645. |
we performed a network meta-analysis to build clear hierarchies of efficacy and tolerability of antipsychotics to augment serotonin reuptake inhibitors (sris) for treatment-resistant obsessive-compulsive disorder (ocd) in adults. |
2020-06-17 |
2023-08-13 |
Not clear |
| Chittaranjan Andrad. Augmentation With Memantine in Obsessive-Compulsive Disorder. The Journal of clinical psychiatry. vol 80. issue 6. 2020-05-27. PMID:31846244. |
patients with obsessive-compulsive disorder (ocd) who do not respond adequately to serotonin reuptake inhibitor (sri) therapy and cognitive behavioral therapy commonly receive sri augmentation in the form of an atypical antipsychotic drug. |
2020-05-27 |
2023-08-13 |
Not clear |
| Mojtaba Sharafkhah, Mobina Aghakarim Alamdar, Ali Massoudifar, Ali Abdolrazaghnejad, Mohsen Ebrahimi-Monfared, Reza Saber, Abolfazl Mohammadbeig. Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. International clinical psychopharmacology. vol 34. issue 5. 2020-04-02. PMID:31058716. |
a randomized clinical trial conducted on 135 patients with a diagnostic and statistical manual of mental disorders-iv (dsm-iv) diagnosis of obsessive-compulsive disorder, who were treatment-resistant and receiving stable treatment with selective serotonin reuptake inhibitors and antipsychotic, received 14 weeks (phase i, intervention period) of placebo (n = 45), ondansetron (n = 45, 4 mg), and granisetron (n = 45, 2 mg) daily augmentations. |
2020-04-02 |
2023-08-13 |
Not clear |
| Karthik Sheshachala, Janardhanan C Narayanaswam. Glutamatergic augmentation strategies in obsessive-compulsive disorder. Indian journal of psychiatry. vol 61. issue Suppl 1. 2020-02-25. PMID:30745678. |
proven treatment strategies for obsessive-compulsive disorder (ocd) include pharmacotherapy with serotonin reuptake inhibitors and cognitive behavior therapy (cbt). |
2020-02-25 |
2023-08-13 |
Not clear |
| Shayanth M Gowda, Janardhanan C Narayanaswamy, Nandita Hazari, Anushree Bose, Harleen Chhabra, Srinivas Balachander, Binukumar Bhaskarapillai, Venkataram Shivakumar, Ganesan Venkatasubramanian, Y C Janardhan Redd. Efficacy of pre-supplementary motor area transcranial direct current stimulation for treatment resistant obsessive compulsive disorder: A randomized, double blinded, sham controlled trial. Brain stimulation. vol 12. issue 4. 2019-12-06. PMID:30808612. |
a significant proportion of obsessive compulsive disorder (ocd) patients do not respond to specific serotonin reuptake inhibitors (ssris). |
2019-12-06 |
2023-08-13 |
Not clear |
| I. Gyertyá. Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying. Behavioural pharmacology. vol 6. issue 1. 2019-11-20. PMID:11224308. |
marble burying has been suggested as a model of obsessive-compulsive disorder (ocd) based on the fact that specific serotonin reuptake inhibitors selectively influenced this response. |
2019-11-20 |
2023-08-12 |
mouse |
| Mendel Fux, Jonathan Benjamin, R. H. Belmake. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. The international journal of neuropsychopharmacology. vol 2. issue 3. 2019-11-20. PMID:11281989. |
inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. |
2019-11-20 |
2023-08-12 |
Not clear |
| Mendel Fux, Jonathan Benjamin, R. H. Belmake. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. The international journal of neuropsychopharmacology. vol 2. issue 3. 2019-11-20. PMID:11281989. |
current serotonin reuptake inhibitor (sri) treatments for obsessive-compulsive disorder (ocd) provide only partial benefit. |
2019-11-20 |
2023-08-12 |
Not clear |
| Craig J. Kinnear, Dana J. H. Niehaus, Johanna C. Moolman-Smook, Pieter L. du Toit, Jeanine van Kradenberg, Jakobus B. Weyers, Annemarie Potgieter, Vanessa Marais, Robin A. Emsley, James A. Knowles, Valerie A. Corfield, Paul A. Brink, Dan J. Stei. Obsessive-compulsive disorder and the promoter region polymorphism (5-HTTLPR) in the serotonin transporter gene (SLC6A4): a negative association study in the Afrikaner population. The international journal of neuropsychopharmacology. vol 3. issue 4. 2019-11-20. PMID:11343612. |
obsessive-compulsive disorder and the promoter region polymorphism (5-httlpr) in the serotonin transporter gene (slc6a4): a negative association study in the afrikaner population. |
2019-11-20 |
2023-08-12 |
human |
| Craig J. Kinnear, Dana J. H. Niehaus, Johanna C. Moolman-Smook, Pieter L. du Toit, Jeanine van Kradenberg, Jakobus B. Weyers, Annemarie Potgieter, Vanessa Marais, Robin A. Emsley, James A. Knowles, Valerie A. Corfield, Paul A. Brink, Dan J. Stei. Obsessive-compulsive disorder and the promoter region polymorphism (5-HTTLPR) in the serotonin transporter gene (SLC6A4): a negative association study in the Afrikaner population. The international journal of neuropsychopharmacology. vol 3. issue 4. 2019-11-20. PMID:11343612. |
a polymorphism (5-httlpr) in the promoter region of the serotonin transporter gene (slc6a4) has been reported to have functional significance and to be associated with obsessive-compulsive disorder (ocd). |
2019-11-20 |
2023-08-12 |
human |
| Emanuela Mundo, Frédéric Rouillon, M. Luisa Figuera, Michael Stigle. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Human psychopharmacology. vol 16. issue 6. 2019-11-20. PMID:12404554. |
some meta-analyses have suggested that the selective serotonin reuptake inhibitors (ssris) are less effective than clomipramine in the treatment of obsessive-compulsive disorder (ocd). |
2019-11-20 |
2023-08-12 |
Not clear |
| Boris Nemets, Mendel Fux, Joseph Levine, R. H Belmake. Combination of antidepressant drugs: the case of inositol. Human psychopharmacology. vol 16. issue 1. 2019-11-20. PMID:12404596. |
inositol is a second messenger precursor that is effective in depression and obsessive-compulsive disorder via a mechanism different from serotonin reuptake inhibitors. |
2019-11-20 |
2023-08-12 |
Not clear |
| Bryan L Roth, David A Shapir. Insights into the structure and function of 5-HT(2) family serotonin receptors reveal novel strategies for therapeutic target development. Expert opinion on therapeutic targets. vol 5. issue 6. 2019-11-20. PMID:12540278. |
5-ht(2) family serotonin receptors, principal sites of action of serotonin in the brain, represent major molecular targets for drugs used in treating a variety of diseases including schizophrenia, depression, anxiety, eating disorders, obsessive-compulsive disorder, chronic pain conditions and obesity. |
2019-11-20 |
2023-08-12 |
Not clear |
| Bernardo DellʼOsso, Beatrice Benatti, Alfredo Carlo Altamura, Eric Hollande. Prevalence of Selective Serotonin Reuptake Inhibitor-Related Apathy in Patients With Obsessive Compulsive Disorder. Journal of clinical psychopharmacology. vol 36. issue 6. 2019-11-20. PMID:27631577. |
prevalence of selective serotonin reuptake inhibitor-related apathy in patients with obsessive compulsive disorder. |
2019-11-20 |
2023-08-13 |
Not clear |
| Vlasios Brakoulias, Emmanouil Tsalamanio. Pharmacotherapy for obsessive-compulsive disorder (OCD): predicting response and moving beyond serotonin re-uptake inhibitors. Expert opinion on pharmacotherapy. vol 18. issue 1. 2019-11-20. PMID:27756176. |
pharmacotherapy for obsessive-compulsive disorder (ocd): predicting response and moving beyond serotonin re-uptake inhibitors. |
2019-11-20 |
2023-08-13 |
Not clear |
| Kasper D Tidemand, Hans E M Christensen, Niclas Hoeck, Pernille Harris, Jane Boesen, Günther H Peter. Stabilization of tryptophan hydroxylase 2 by l-phenylalanine-induced dimerization. FEBS open bio. vol 6. issue 10. 2019-11-20. PMID:27761358. |
tryptophan hydroxylase 2 (tph2) catalyses the initial and rate-limiting step in the biosynthesis of serotonin, which is associated with a variety of disorders such as depression, obsessive compulsive disorder, and schizophrenia. |
2019-11-20 |
2023-08-13 |
human |
| Umberto Albert, Gabriele Di Salvo, Francesca Solia, Gianluca Rosso, Giuseppe Main. Combining Drug and Psychological Treatments for Obsessive- Compulsive Disorder: What is the Evidence, When and for Whom. Current medicinal chemistry. vol 25. issue 41. 2019-10-01. PMID:28707590. |
serotonin reuptake inhibitors (sris) and cognitive-behavioral psychotherapy (cbt) are first-line treatments for obsessive-compulsive disorder (ocd). |
2019-10-01 |
2023-08-13 |
Not clear |
| Umberto Albert, Donatella Marazziti, Gabriele Di Salvo, Francesca Solia, Gianluca Rosso, Giuseppe Main. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy. Current medicinal chemistry. vol 25. issue 41. 2019-10-01. PMID:29278206. |
serotonin reuptake inhibitors (sris) and cognitive-behavioral psychotherapy (cbt) are first-line treatments for obsessive-compulsive disorder (ocd). |
2019-10-01 |
2023-08-13 |
Not clear |
| Christina L Boisseau, Steven A Rasmusse. Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods. Contemporary clinical trials. vol 65. 2019-05-28. PMID:29306047. |
unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: study protocol and methods. |
2019-05-28 |
2023-08-13 |
Not clear |